A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Mark Hertzberg,Matthew Ku,Olivier Catalani,Betsy Althaus,Steven Simko,Gareth P. Gregory

A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

2021

Mark Hertzberg
Matthew Ku
Olivier Catalani
Betsy Althaus
Steven Simko
Gareth P. Gregory

TPS7575Background: Prognosis is poor for patients with R/R DLBCL, particularly those who are ineligible for autologous stem cell transplant (ASCT) or who relapse after second-line therapy (Gisselbr...

Keywords:

Medicine
Oxaliplatin
Internal medicine
Gemcitabine
Stem cell
in patient
Oncology
Rituximab
relapsed refractory
Diffuse large B-cell lymphoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations